Time dependent alterations of co-localization of S100β and GFAP in the MPTP-treated mice
- 1 June 2006
- journal article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 113 (12) , 1887-1894
- https://doi.org/10.1007/s00702-006-0482-x
Abstract
S100β is a calcium-binding peptide produced by astrocytes. This protein is expressed at high levels in brain and is known as a marker of brain damage. However, little is known about the role of S100β protein during neuronal damage caused by MPTP. To determine exactly changes of expression of S100β protein in relation to changes of glial cells, we investigated immunohistochemically the expression of S100β protein using MPTP-treated mice. The present study showed that tyrosine hydroxylase (TH) immunoreactivity was decreased in the striatum and substantia nigra from 5 h and 1 day after MPTP treatment, respectively. Thereafter, a severe reduction in TH immunoreactivity was observed in the striatum and substantia nigra 1, 3 and 7 days after MPTP treatment. In our double-labeled immunostaining, the number of S100-positive/GFAP-negative cells decreased from 1 day up to 7 days after MPTP treatment. In contrast, the number of double-labeled S100/GFAP-immnoreactive cells increased from 1 day up to 7 days after MPTP treatment. The number of S100β-positive/GFAP-negative cells also decreased 3 and 7 days after MPTP treatment. In contrast, the number of double-labeled S100β/GFAP-immunoreactive cells increased from 1 day up to 7 days after MPTP treatment. The present study demonstrates that S100β/GFAP-positive cells may play some role in the pathogenesis of MPTP-induced dopaminergic neurodegeneration in the striatum. The present results also suggest the presence of the S100β protein in a subpopulation of GFAP-negative astrocytes in the striatum after MPTP treatment. These results suggest that the modulation of astrocytic activation may offer a novel therapeutic strategy of Parkinson’s disease.Keywords
This publication has 40 references indexed in Scilit:
- Alterations of Interneurons of the Gerbil Hippocampus after Transient Cerebral Ischemia: Effect of PitavastatinNeuropsychopharmacology, 2005
- Effect of pitavastatin against expression of S100β protein in the gerbil hippocampus after transient cerebral ischaemiaActa Physiologica Scandinavica, 2004
- S100 immunoreactive glial cells in the forebrain and midbrain of the lizard Gallotia galloti during ontogenyJournal of Neurobiology, 2003
- Astrocytic Activation and Delayed Infarct Expansion after Permanent Focal Ischemia in Rats. Part II: Suppression of Astrocytic Activation by a Novel Agent (R)-(−)-2-propyloctanoic acid (ONO-2506) Leads to Mitigation of Delayed Infarct Expansion and Early Improvement of Neurologic DeficitsJournal of Cerebral Blood Flow & Metabolism, 2002
- S-100β protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosisNeuroscience Letters, 1999
- Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndromeBrain Research, 1997
- The S100 family of EF-hand calcium-binding proteins: functions and pathologyTrends in Biochemical Sciences, 1996
- 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particlesBiochemical and Biophysical Research Communications, 1990
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984